| | Identification | Back Directory |  | [Name] 
 N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
 |  | [CAS] 
 477600-74-1
 |  | [Synonyms] 
 TF-G
 Tofacitinib-11
 Tofacitinib IMpurity M
 tofacitinib intermediate
 Tofacitinib N-Descyanoacetyl
 H-Pyrrolo[2,3-d]pyriMidin-4-aMine
 Tofacitinib N-Descyanoacetyl Impurity
 N-Methyl-N-[(3R,4R)-4-Methylpiperidin-3-yl]-7H-pyrrolo[2,3-d]
 (3R,4R)-N,4-diMethyl-N-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}piperidin-3-aMine
 N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
 N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amin
 N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-1H-pyrrolo[2,3-d]pyrimidin-4-amine
 N-methyl-N-((3S,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
 N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
 (3R,4R)-Methyl{(4-Methylpiperidin-3-yl)(7H-pyrrolo[2,3-d]pyriMidin-4-yl)}aMine
 7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-3-piperidinyl]-
 1H-Pyrrolo[2,3-d]pyriMidin-4-aMine,N-Methyl-N-[(3R,4R)-4-Methyl-3-piperidinyl]- (9CI)
 N-Methyl-N-((3R,4R)-4-Methyl-piperidin-3-yl)-N-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine
 N-METHYL-N-((3R,4R)-4-METHYLPIPERIDIN-3-YL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE (CAS NO.477600-74-1)
 Tofacitinib impurity 7/N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine
 N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7HMethylpiperidin-3-yl)-7Hpyrrolo[
2,3-d]pyriMidin-4-aMine
 |  | [Molecular Formula] 
 C13H19N5
 |  | [MDL Number] 
 MFCD09878608
 |  | [MOL File] 
 477600-74-1.mol
 |  | [Molecular Weight] 
 245.323
 | 
 | Chemical Properties | Back Directory |  | [Melting point ] 
 157 - 162°C
 |  | [density ] 
 1?+-.0.06 g/cm3(Predicted)
 |  | [storage temp. ] 
 Keep in dark place,Sealed in dry,2-8°C
 |  | [solubility ] 
 Aqueous Acid (Slightly), Methanol (Slightly), Water (Slightly, Heated)
 |  | [form ] 
 Solid
 |  | [pka] 
 13.36±0.50(Predicted)
 |  | [color ] 
 White to Off-White
 |  | [InChI] 
 InChI=1S/C13H19N5/c1-9-3-5-14-7-11(9)18(2)13-10-4-6-15-12(10)16-8-17-13/h4,6,8-9,11,14H,3,5,7H2,1-2H3,(H,15,16,17)/t9-,11+/m1/s1
 |  | [InChIKey] 
 XRIARWQZLGCQDM-KOLCDFICSA-N
 |  | [SMILES] 
 C1=NC(N(C)[C@@H]2[C@H](C)CCNC2)=C2C=CNC2=N1
 | 
 | Hazard Information | Back Directory |  | [Description] 
 N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(477600-74-1) is an important pharmaceutical intermediate that is a by-product of the preparation of tofacitinib. Tofacitinib belongs to a class of Janus kinase (JAK) inhibitors used in the treatment of rheumatoid arthritis and psoriatic arthritis.
 |  | [Uses] 
 N-Methyl-N-((3S,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine(477600-74-1), is an intermediate in the synthesis of (3S,4R)-Tofacitinib (T528010), an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases.
 | 
 |  |